Stockscreener 앱 받기
44.95
7.28%
-3.53
Anaptysbio Inc 주식(ANAB)의 최신 뉴스
Is AnaptysBio Inc AN6 a good long term investmentTrading Volume Surges & High Profit Investment Ideas - earlytimes.in
New Highs: Is AnaptysBio Inc stock a safe haven assetEarnings Growth Report & AI Forecasted Stock Moves - moha.gov.vn
This biotech stock has more than tripled in 2025, but red flags are waving - MSN
AnaptysBio (NASDAQ:ANAB) Stock Price Down 4%Should You Sell? - MarketBeat
Trade Alert: Independent Director Of AnaptysBio J. Ware Has Sold Stock - simplywall.st
AnaptysBio (NASDAQ:ANAB) Hits New 12-Month HighTime to Buy? - MarketBeat
AnaptysBio stock hits 52-week high at $51.58 - Investing.com
AnaptysBio stock hits 52-week high at $51.58 By Investing.com - Investing.com Canada
Insider Selling: AnaptysBio (NASDAQ:ANAB) Director Sells 3,900 Shares of Stock - MarketBeat
AnaptysBio (NASDAQ:ANAB) Insider Sells $75,000.00 in Stock - MarketBeat
AnaptysBio (NASDAQ:ANAB) CFO Dennis Mulroy Sells 10,000 Shares - MarketBeat
AnaptysBio (NASDAQ:ANAB) Insider Eric Loumeau Sells 10,000 Shares - MarketBeat
Anaptysbio Insider Sold Shares Worth $510,000, According to a Recent SEC Filing - marketscreener.com
Anaptysbio Insider Sold Shares Worth $500,000, According to a Recent SEC Filing - marketscreener.com
AnaptysBio Executives and Director Execute Stock Sales - TradingView — Track All Markets
AnaptysBio Executives Sell Shares - TradingView — Track All Markets
AnaptysBio (NASDAQ: ANAB) CMO reports option exercise and stock sale - Stock Titan
AnaptysBio, Inc. (NASDAQ:ANAB) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Is AnaptysBio Inc. stock a buy in volatile marketsDip Buying & AI Enhanced Market Trend Forecasts - Улправда
AnaptysBio sets $100M stock repurchase plan - MSN
How AnaptysBio Inc. (AN6) stock trades under stagflationJuly 2025 Spike Watch & Smart Allocation Stock Reports - Улправда
This Biotech Stock Has More Than Tripled in 2025, but Red Flags Are Waving - Yahoo Finance
Will AnaptysBio Inc. stock reach Wall Street targetsQuarterly Market Review & Consistent Income Trade Recommendations - DonanımHaber
What dividend safety score for AnaptysBio Inc. stockNew Guidance & Consistent Growth Stock Picks - Bölüm Sonu Canavarı
Is AnaptysBio Inc. stock recession proofIPO Watch & Capital Efficiency Focused Strategies - DonanımHaber
AnaptysBio, Inc. $ANAB Shares Bought by Assenagon Asset Management S.A. - MarketBeat
AnaptysBio (STU:AN6) EV-to-OCF : -6.99 (As of Dec. 19, 2025) - GuruFocus
AnaptysBio (NASDAQ:ANAB) Sets New 1-Year HighWhat's Next? - MarketBeat
AnaptysBio (NASDAQ:ANAB) CFO Sells $705,266.25 in Stock - MarketBeat
Eric Loumeau Sells 10,000 Shares of AnaptysBio (NASDAQ:ANAB) Stock - MarketBeat
AnaptysBio (NASDAQ:ANAB) Insider Eric Loumeau Sells 12,500 Shares - MarketBeat
Avoiding Lag: Real-Time Signals in (ANAB) Movement - Stock Traders Daily
AnaptysBio (ANAB) CFO option exercise and Rule 10b5-1 share sale detailed - Stock Titan
AnaptysBio stock hits 52-week high at 47.95 USD - Investing.com
AnaptysBio stock hits 52-week high at 47.95 USD By Investing.com - Investing.com Nigeria
Squarepoint Ops LLC Invests $2.43 Million in AnaptysBio, Inc. $ANAB - MarketBeat
AnaptysBio (ANAB) Receives a Buy from Wells Fargo - The Globe and Mail
AnaptysBio (ANAB) Price Target Lowered by Barclays, Maintains Ov - GuruFocus
Officer Loumeau Files To Sell 12,500 Of AnaptysBio Inc [ANAB] - TradingView — Track All Markets
Vanda submits BLA to FDA for generalized pustular psoriasis drug By Investing.com - Investing.com Nigeria
Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis - marketscreener.com
Vanda (Nasdaq: VNDA) seeks priority FDA review of BLA for GPP drug imsidolimab - Stock Titan
JP Morgan maintains a sell rating on GSK plc (GSK) - MSN
683 Capital Management LLC Has $11.10 Million Stock Holdings in AnaptysBio, Inc. $ANAB - MarketBeat
Camber Capital Management LP Sells 625,000 Shares of AnaptysBio, Inc. $ANAB - MarketBeat
AnaptysBio stock hits 52-week high at 46.57 USD - Investing.com
AnaptysBio stock hits 52-week high at 46.57 USD By Investing.com - Investing.com Canada
Stifel Nicolaus Lowers AnaptysBio (NASDAQ:ANAB) Price Target to $56.00 - MarketBeat
AnaptysBio (ANAB) Analyst Rating Update: Stifel Lowers Price Tar - GuruFocus
Beyond the Gluten-Free Diet: A New Era in Celiac Disease Treatment - BioSpace
J&J sends AnaptysBio lower with mid-stage trial data for anti-inflammatory agent - MSN
J.P. Morgan Maintains a Sell Rating on GSK plc (GSK) - Finviz
0.57%
자본화:
|
볼륨(24시간):